Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...
GeneTAC® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1 ...
Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that ...
LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive ...
AnteoTech has completed the first stage of a collaborative development program assessing how well its AnteoBind NXT activates ...
Proven bacterial, viral, conjugate, and E.coli expression platforms support partners from discovery and process development to GMP readiness and clinical manufacturing ...
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA's decision follows positive Phase 1 results for GT-02287 in both healthy ...
Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies ...
As renewable penetration rises across Europe, CATL says the energy storage market is entering a more demanding phase, where system design, long-term reliability, financing confidence and local service ...
Backed by data-driven insight, Sharon Bligh from the Consumer Goods Forum cuts to the heart of how manufacturers can get ...
Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.
Frankel's investment in dpHUE offers a look inside the playbook she's developed since Skinnygirl, one focused on scaling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results